Avandia, the GlaxoSmithKline drug that has been under intense scrutiny in the media for several months following disputes over its safety, might not be the only major diabetes drug facing questions. The drug’s rocky road is damaging company profits.
Rumours in America are that the Food and Drug Administration could also ask questions over the safety of Actos. Actos works in a similar way to Avandia, and is one of the drug’s main competitors. Actos is manufactured by Takeda Pharmaceuticals.
Actos is the subject of an FDA advisory committee meeting about the safety of thiazolidinediones, one class of drugs for diabetics. The FDA, perhaps seeking to downplay media speculatio, reportedly commented: “An important part of the context is that there are risks of all diabetic drugs.”
Actos is a significant part of the Takeda annual profit. In response to the Avandia controversy, Actos actually initially benefited. A spokesman for Takeda, Matt Kuh, reportedly commented: “Takeda thinks it’s appropriate to reserve comment until after Monday, when many important questions will be posed and discussion will occur by the FDA and leading diabetes experts.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…